Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma.

MLA

Yujing Xin, et al. “Efficacy and Safety of Atezolizumab plus Bevacizumab Combined with Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma.” Frontiers in Immunology, vol. 13, Aug. 2022, pp. 1–11. EBSCOhost, https://doi.org/10.3389/fimmu.2022.929141.

APA

Yujing Xin, Fei Cao, Hongcai Yang, Xinyuan Zhang, Yi Chen, Xiaojing Cao, Xiang Zhou, Xiao Li, & Jinxue Zhou. (2022). Efficacy and safety of atezolizumab plus bevacizumab combined with hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma. Frontiers in Immunology, 13, 1–11. https://doi.org/10.3389/fimmu.2022.929141

Chicago

Yujing Xin, Fei Cao, Hongcai Yang, Xinyuan Zhang, Yi Chen, Xiaojing Cao, Xiang Zhou, Xiao Li, and Jinxue Zhou. 2022. “Efficacy and Safety of Atezolizumab plus Bevacizumab Combined with Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma.” Frontiers in Immunology 13 (August): 1–11. doi:10.3389/fimmu.2022.929141.